Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-05-13 00:00:00 ET · period of report 2024-05-09 · accession 0002001011-24-000051 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-13 | 2024-05-09 | LGND | Reardon Andrew | CLO | M - OptEx | $52.27 | +10.0K | 32.2K | +45% | +$522.7K |
| D | 2024-05-13 | 2024-05-09 | LGND | Reardon Andrew | CLO | S - Sale+OE | $83.04 | -10.0K | 22.2K | -31% | -$830.4K |
| D | 2024-05-13 | 2024-05-09 | LGND | Reardon Andrew | CLO | M - OptEx | $0.00 | -10.0K | 62.9K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-09 | M | A | 10,000 | $52.27 | 32,205 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-09 | S | D | 10,000 | $83.04 | 22,205 | D | — | — | (F1) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.27. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-05-09 | M | D | 10,000 | $0.00 | 62,944 | D | $52.27 · — to 2032-08-01 | 10,000 Common Stock | (F2) The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. |